Burnaby, British Columbia – (Newsfile Corp. – August 24, 2021) – Advanced Proteome Therapeutics Corporation (TSXV: APC) (FSE: 0E8) (“APC” or the “Company”), reports that its US subsidiary, Advanced Proteome Therapeutics Inc. (“APTI”) is devoting additional resources to its SARS-CoV-2 protease inhibitor program.
As previously announced, APTI scientists have identified several compounds with a predicted high affinity for the major SARS-CoV-2 protease through in silico modeling and synthesis efforts and preliminary tests have been initiated. In the fall of last year, the program was downgraded due to the arrival of highly effective vaccines on the market and the promise that the COVID pandemic could be brought under control.
As the pandemic continues and SARS-CoV-2 is likely to be an endemic virus with new variants that elude current vaccines, APTI plans to reallocate resources to the development of SARS protease inhibitors -CoV-2. The main protease of SARS-CoV-2 is expected to be highly conserved as the virus evolves and therefore constitutes an optimal therapeutic target.
APTI hired Dr Michael Angelastro to advise on this project. Dr. Angelastro has spent more than 30 years in the large pharmaceutical companies of Sanofi and its historic companies, reaching the role of Senior Principal Scientist. During his career, he has synthesized several clinical candidates, including cysteine and serine protease inhibitors. The cysteine protease inhibitors he synthesized have been successful on earlier screens for the SARS-CoV-2 protease.
The first step in revisiting the program will be to confirm our previous successes and run an enlarged screen using more powerful modeling software. This will be followed by the synthesis of additional compounds and the test activity on the main protease of SARS-CoV-2 before proceeding to the tests on the live virus.
The allocation of resources to this project is continued in such a way that it does not have a significant impact on our research and development of basic antibody-drug conjugates.
APTI CEO Dr Benjamin Krantz said: “The dynamics of the COVID pandemic have made it clear that the variants of SARS-CoV-2 will stay with us and over time new variants will emerge. Especially in the face of vaccine hesitation and the potential for decreased vaccine efficacy, treatment against a conserved target such as the main protease of SARS-CoV-2 is in great need. Therefore, the time has come to re-dedicate resources to this project. We have already identified successes with our previous modeling. efforts, and we’re excited to use more powerful tools to further validate our approach. In addition, the engagement of Dr Michael Angelastro as an advisor on this project will bring decades of synthetic chemistry expertise to this space and valuable information about the project. “
Dr Michael Angelastro commented: “I am delighted to be working with Advanced Proteome on this project. The approach taken by APT has the ability to generate protease inhibitors with significantly improved activity and pharmacokinetics compared to typical small molecule approaches. I plan to postulate lessons learned from my 30 years of experience in optimizing the pharmacological properties of structures identified by APT computer-aided drug design. Modeling to date has produced molecules with high predicted activity and l The general approach has potential therapeutic applications beyond SARS-Protease CoV-2. I look forward to contributing to the development of a platform that will be able to rapidly deliver analogs of the pharmacophore APT to inhibit protease targets of the future with a focus on viral proteases.
The Company makes no express or implied representation that it has the ability to eliminate, cure or contain Covid-19 (or the SARS-2 coronavirus) at this time.
ABOUT THE COMPANY:
Advanced Proteome Therapeutics Corporation, through its subsidiary Advanced Proteome Therapeutics Inc., has invented a proprietary protein conjugation technology that enables the development of superior antibody-drug conjugates through better site-specific labeling, control of the ratio drug-antibody and activation of combined payloads. The technology has compelling preclinical data demonstrating improved homogeneity and increased in vivo potency compared to current advanced linker technology. The Company believes that the technology will enable the development of safer and more potent antibody-drug conjugate therapies and pursues licensing and partnership opportunities to advance development and create shareholder value.
FOR MORE INFORMATION, PLEASE CONTACT:
Advanced Proteome Therapeutics Corporation
President and CEO
Phone. : (604)690-3797
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
This press release contains forward-looking statements relating to the Company’s future operations and other statements which are not historical facts. Forward-looking statements are often identified by words such as “will”, “may”, “should”, “intend”, “anticipate”, “expect” and similar expressions. All statements other than statements of historical fact included in this press release, including, without limitation, statements regarding the future plans and objectives of the Company, are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and that actual results and future events could differ materially from those anticipated in such statements. The significant factors that could cause actual results to differ materially from the Company’s expectations are the risks detailed from time to time in documents filed by the Company with securities regulatory authorities.
Readers are cautioned that the assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those expected, due to many known and unknown risks, uncertainties and other factors, many of which are beyond the control of the Company. Accordingly, the Company cannot guarantee that a forward-looking statement will materialize, and readers should not place undue reliance on forward-looking information. This information, although considered reasonable by management at the time of its preparation, may prove to be incorrect and actual results may differ materially from those anticipated. The forward-looking statements contained in this press release are expressly qualified by this cautionary statement. The forward-looking statements contained in this press release are made as of the date of this press release, and the Company will not publicly update or revise the included forward-looking statements except as expressly required by Canadian securities laws.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/94212.